Compare Neurocrine Biosciences Inc (NBIX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Otis Worldwide Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.37 (market cap $14.36B), while Otis Worldwide Corp trades at $65.83 (market cap $25.17B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.66% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Otis Worldwide Corp for 65 Days on average.
| NBIX | OTIS | |
|---|---|---|
Market Cap | $14.36B | $25.17B |
Volume | 1,237,180 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $185.50 | $93.62 |
52-Week Low | $123.10 | $64.05 |
Typical Hold Time | 23 Days | 65 Days |
Enterprise Value | $14.37B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Otis Worldwide trades at $65.74, down 1.07% with a bearish technical signal and recent earnings misses. The stock trades near its 52-week low with mixed analyst sentiment (46.7% buy, 46.7% hold) despite a consensus price target of $87.00. Revenue growth remains stable at $14.43B (2025) with 10.17% net margins, though service margins face pressure from labor costs. Recent CEO succession news and China project wins provide strategic context amid weak equipment demand.
The outlook balances stable service revenue against margin pressures and China exposure. Upside exists if service margins recover and modernization backlog converts, but near-term headwinds and technical weakness suggest cautious positioning. Key risks include prolonged China weakness and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
